As Trump Announces New Plan on Opioids, DOJ is Already Hard at Work

The DOJ has focused particularly on the payment of kickbacks that induce physicians to prescribe more, or more expensive, opioids.

Last week, President Trump unveiled the administration’s new plan to combat the opioid epidemic. In 2016, more than 11 million Americans misused prescription opioids, resulting in 42,000 related deaths and $504 billion in related economic costs. The plan includes stiffer penalties for high-volume drug dealers, including seeking the death penalty where it is appropriate under current law, and a stated goal to reduce prescriptions of the powerful painkillers by one-third nationwide.

Long before this week’s announcement, however, the U.S. Department of Justice (DOJ) has been hard at work on these goals. Last summer, as we reported on Monitor Monday, Attorney General Jeff Sessions announced opioid-related healthcare fraud as a priority for the agency. In 2017, 34 percent of defendants charged by the Medicare Fraud Strike Force were charged with crimes involving opioid prescriptions.

The DOJ has focused particularly on the payment of kickbacks that induce physicians to prescribe more, or more expensive, opioids. This in violation of a law known as “the anti-kickback statute,” which prohibits medical providers from paying or receiving kickbacks, remuneration, or anything of value in exchange for referrals of patients who will receive treatment paid for by government healthcare programs, such as Medicare and Medicaid. The law is designed to keep medical treatment decisions free from the influence of potential monetary gain. As the DOJ has explained, “[p]atients are entitled to be sure that the care they receive is based on their actual medical needs rather than the financial interests of their physicians.” Violations of the anti-kickback law can also be violations of the False Claims Act, which allows private citizens to blow the whistle on fraud against the government, and share in the amount recovered.

Last October, Dr. John Kapoor, the chief executive officer of Insys Therapeutics, a manufacturer of fentanyl (a powerful opioid), was charged with violations of the False Claims Act. Prosecutors alleged the company paid hundreds of thousands of dollars to doctors in exchange for prescribing a spray called Subsys that contained fentanyl; Subsys is 100 times stronger than morphine. The scheme was brought to light by a whistleblower who was a former Insys employee. Dr. Kapoor pleaded not guilty in November, and the case is ongoing.

Two weeks ago, one of the doctors who received payments from Insys was sentenced to 51 months in prison by a federal court in Rhode Island. Dr. Jerrold Rosenberg, whose sentencing hearing included testimony from three former patients about the debilitating effects they experienced from the drug, received over $180,000 in payments from the company. His son was also a sales representative for Insys. In addition to jail time, Dr. Rosenberg will also have to pay Medicare over $750,000 in restitution due to his overprescribing of the spray.

Just last Friday, prosecutors in New York charged five more doctors with accepting kickbacks from Insys. All five allegedly received lavish payments from the company that were disguised as speaking fees, and totaled hundreds of thousands of dollars. Each one of the doctors charged also prescribed over $500,000 of Subsys in a single quarter.

With many related actions involving the kickback scheme currently ongoing, this will be a case to watch.

 

Comment on this article

Print Friendly, PDF & Email
Facebook
Twitter
LinkedIn
Email
Print

Related Stories

Leave a Reply

Please log in to your account to comment on this article.

Featured Webcasts

Mastering the Two-Midnight Rule: Keys to Navigating Short-Stay Admissions with Confidence

Mastering the Two-Midnight Rule: Keys to Navigating Short-Stay Admissions with Confidence

The CMS Two-Midnight Rule and short-stay audits are here to stay, impacting inpatient and outpatient admissions, ASC procedures, and Medicare Parts C & D. New for 2024, the Two-Midnight Rule applies to Medicare Advantage patients, requiring differentiation between Medicare plans affecting Case Managers, Utilization Review, and operational processes and knowledge of a vital distinction between these patients that influences post-discharge medical reviews and compliance risk. Join Michael G. Calahan for a comprehensive webcast covering federal laws for all admission processes. Gain the knowledge needed to navigate audits effectively and optimize patient access points, personnel, and compliance strategies. Learn Two-Midnight Rule essentials, Medicare Advantage implications, and compliance best practices. Discover operational insights for short-stay admissions, outpatient observation, and the ever-changing Inpatient-Only Listing.

Print Friendly, PDF & Email
September 19, 2023
Secondary Diagnosis Coding: A Deep Dive into Guidelines and Best Practices

Secondary Diagnosis Coding: A Deep Dive into Guidelines and Best Practices

Explore comprehensive guidelines and best practices for secondary diagnosis coding in our illuminating webcast. Delve into the intricacies of accurately assigning secondary diagnosis codes to ensure precise medical documentation. Learn how to navigate complex scenarios and adhere to coding regulations while enhancing coding proficiency. Our expert-led webcast covers essential insights, including documentation requirements, sequencing strategies, and industry updates. Elevate your coding skills and stay current with the latest coding advancements so you can determine the correct DRG assignment to optimize reimbursement, support medical decision-making, and maintain compliance.

Print Friendly, PDF & Email
September 20, 2023
Principal Diagnosis Coding: Mastering Selection and Sequencing

Principal Diagnosis Coding: Mastering Selection and Sequencing

Enhance your inpatient coding precision and revenue with Principal Diagnosis Coding: Mastering Selection and Sequencing. Join our expert-led webcast to conquer the challenges of principal diagnosis selection and sequencing. We’ll decode the intricacies of ICD-10-CM guidelines, equipping you with a clear grasp of the rules and the official UHDDS principal diagnosis definition. Uncover the crucial role of coding conventions, master the sequencing of related conditions, and confidently tackle cases with equally valid principal diagnoses.

Print Friendly, PDF & Email
September 14, 2023
2024 IPPS Summit: Final Rule Update with Expert Insights and Analysis

2024 IPPS Summit: Final Rule Update with Expert Insights and Analysis

Only ICD10monitor delivers what you need: updates on must-know changes associated with the FY24 Inpatient Prospective Payment System (IPPS) Final Rule, including new ICD-10-CM/PCS codes, plus insights, analysis and answers to questions from the country’s most respected subject matter experts.

Print Friendly, PDF & Email
2024 IPPS Summit Day 3: MS-DRG Shifts and NTAPs

2024 IPPS Summit Day 3: MS-DRG Shifts and NTAPs

This third session in our 2024 IPPS Summit will feature a review of FY24 changes to the MS-DRG methodology and new technology add-on payments (NTAPs), presented by senior healthcare consultant Laurie Johnson, with bonus insights and analysis from two acclaimed subject matter experts

Print Friendly, PDF & Email
August 17, 2023

Trending News